The 31st National High School Manga Championship (Manga Koshien)
12.4.2022 09:00:00 EEST | Business Wire | Press release
What is Manga Koshien?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220408005170/en/
Flyer (Graphic: Business Wire)
It is a competition where teams of high school students compete on manga creations. This competition started in 1992 and celebrated its 30th anniversary last year. Since 2014, schools from overseas also started entering the competition, and we are seeing approximately 300 schools participating each year from Japan and abroad.
Teams of three to five students each work together to draw a one-page manga in accordance with a specified theme for the preliminaries. Those who manage to pass the preliminaries gather in Kochi during summer for the main round.
Teams in the main round (semifinals, revival round, finals) stand a chance to win the grand prize and other awards. This means prize money, drawing materials, and more! In addition, during the main round, talented students may even be scouted by major manga publishers and perhaps debut as professionals!
1. Preliminary Round Theme
- Space debris (Uchuu Gomi)
- ∞ Infinity (Mugen)
Draw and submit a one-page manga of either one of these themes.
Manga Koshien Website: https://mangaoukoku-tosa.jp/manga-koshien31/
2. Eligibility
- Japan and overseas senior high school students or similar (approximately 15 to 18 years of age)
- Only one team per school is allowed to participate.
3. Guidelines for the Preliminary Round Entries
- Entries should be submitted online at https://mangaoukoku-tosa.jp/manga-koshien31/
- The manga must be of B4 size (257mm x 364mm, in any orientation).
- The manga must be produced jointly by all students registered in the application form.
4. Timeline
(1) Preliminary Round (Online)
- Deadline: Tuesday, May 31st, 2022, 24:00 (JST)
- Judging: Tuesday, June 14th, 2022
- Chosen schools: 33 schools (30 from Japan, 3 from overseas)
(2) Main Round (Kochi Prefecture, Japan)
- Participants: 33 schools that passed the preliminary round
- Date: Saturday, 30th, and Sunday, 31st, July 2022
- Venue: Kochi Jibasan Center
- Participation fee: JPY 30,000 (per person)
*The participation fee will cover the participants’ air ticket, accommodation, etc.
*Travel arrangements will be made by the event organizer
5. Main Round Judges
- All 6 Preliminary Round Judges
-
Guest Judges
Fujimaki Tadatoshi (Famous works: Kuroko no Basuke, Robot x Laserbeam)
Yukimoto Shuuji (Famous works: Kemo Life, Shark Girl)
*For more details, please refer to the Implementation Outline at the following
URL: https://mangaoukoku-tosa.jp/manga-koshien31/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005170/en/
Contact information
In-charge: Yasuaki Okamatsu, Risa Matsumoto
Manga Kingdom Tosa Promotional Committee
(within the Manga Kingdom Tosa Office)
TEL: +81-(0)88-823-9711 FAX: +81-(0)88-823-9296
Email: 140201@ken.pref.kochi.lg.jp
Website: https://mangaoukoku-tosa.jp/manga-koshien31/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom